Home LiteratureArticle Details
PMID: 14523098 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition.

Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, Ruffoli R, Soldani P, Ruggieri S, Alessandri MG, Paparelli A

Abstract

Mutation of genes encoding for various components of a metabolic pathway named the ubiquitin-proteasome system (UP) leads to inherited forms of Parkinson's disease (PD), whereas various components of the UP are constantly present within neuronal inclusions, Lewy bodies, that characterize most genetic and sporadic forms of PD. It has been hypothesized that impairment of this metabolic pathway might be a common mechanism for the onset of PD, and a recent study demonstrated a dysfunction of the UP system within the substantia nigra of patients affected by sporadic PD. In search for the mechanisms underlying the selective toxicity for nigral neurons after inhibition of the UP system, we explored the selective effects after striatal microinfusions of lactacystin or epoxomycin and potential retrograde changes within the ipsilateral substantia nigra. We found that neurotoxicity was selective for striatal dopamine (DA) components and led to retrograde apoptosis within nigral DA cells, which developed neuronal inclusions staining for antigens of the UP system. We found the same ultrastructural features characterizing inclusions obtained in vivo and in vitro after UP inhibition. In vivo, lactacystin-epoxomycin-induced toxicity was suppressed by inhibiting DA synthesis. Similarly, in vitro inclusions and apoptosis were prevented by reducing endogenous DA. On the other hand, toxicity of proteasome inhibition was enhanced by drugs augmenting DA availability: l-3,4-dihydroxyphenylalanine, monoamine oxidase blockers, and DA beta-hydroxylase blockers. These findings demonstrate that impairment of the UP system produces cell death and neuronal inclusions selectively for DA-containing neurons that depend on the occurrence of endogenous DA.

MeSH Terms
3,4-Dihydroxyphenylacetic Acid/metabolism Acetylcysteine/analogs & derivatives,toxicity Animals Cell Death Corpus Striatum/drug effects,metabolism,pathology Cysteine Endopeptidases/metabolism Dopamine/metabolism Dopamine Plasma Membrane Transport Proteins Dose-Response Relationship, Drug Enzyme Inhibitors/toxicity Inclusion Bodies/metabolism,pathology Male Membrane Glycoproteins Membrane Transport Proteins/metabolism Motor Activity/drug effects Multienzyme Complexes/antagonists & inhibitors,metabolism Nerve Tissue Proteins Oligopeptides/toxicity PC12 Cells Pheochromocytoma/drug therapy,metabolism Proteasome Endopeptidase Complex Rats Rats, Sprague-Dawley Signal Transduction/drug effects,physiology Substantia Nigra/drug effects,metabolism,pathology Tyrosine 3-Monooxygenase/metabolism
Chemicals
Dopamine Plasma Membrane Transport Proteins Enzyme Inhibitors Membrane Glycoproteins Membrane Transport Proteins Multienzyme Complexes Nerve Tissue Proteins Oligopeptides 3,4-Dihydroxyphenylacetic Acid lactacystin Tyrosine 3-Monooxygenase Cysteine Endopeptidases Proteasome Endopeptidase Complex Dopamine Acetylcysteine epoxomicin
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Fornai Francesco
Department of Human Morphology and Applied Biology, University of Pisa, I-56100 Pisa, Italy. f.fornai@med.unipi.it
Lenzi Paola
Gesi Marco
Ferrucci Michela
Lazzeri Gloria
Busceti Carla L
Ruffoli Riccardo
Soldani Paola
Ruggieri Stefano
Alessandri Maria G
Paparelli Antonio
References (48)
48 references, click to expand
  1. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
    J Neurosci. 1999 Apr 1;19(7):2424-31 PMID: 10087057
  2. The proteasome, a novel protease regulated by multiple mechanisms.
    J Biol Chem. 1999 Aug 6;274(32):22123-6 PMID: 10428771
  3. Dopamine transporters and neuronal injury.
    Trends Pharmacol Sci. 1999 Oct;20(10):424-9 PMID: 10498956
  4. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study.
    J Neurochem. 1999 Dec;73(6):2434-40 PMID: 10582603
  5. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
    J Neurochem. 2000 Apr;74(4):1656-65 PMID: 10737624
  6. Ubiquitin-mediated proteolysis: biological regulation via destruction.
    Bioessays. 2000 May;22(5):442-51 PMID: 10797484
  7. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
    J Immunol. 2000 Jun 15;164(12):6147-57 PMID: 10843664
  8. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.
    Nat Genet. 2000 Jul;25(3):302-5 PMID: 10888878
  9. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration.
    Brain Res. 2000 Aug 25;874(2):123-30 PMID: 10960596
  10. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.
    Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11869-74 PMID: 11050221
  11. Proteasome inhibitors block intracellular growth and replication of Toxoplasma gondii.
    Parasitology. 2000 Jul;121 ( Pt 1):35-47 PMID: 11085223
  12. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies.
    Exp Neurol. 2000 Dec;166(2):324-33 PMID: 11085897
  13. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
    Science. 2001 Jul 13;293(5528):263-9 PMID: 11431533
  14. Failure of the ubiquitin-proteasome system in Parkinson's disease.
    Nat Rev Neurosci. 2001 Aug;2(8):589-94 PMID: 11484002
  15. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells.
    J Neurochem. 2001 Aug;78(4):899-908 PMID: 11520910
  16. Immunohistochemical evidence and ultrastructural compartmentalization of a new antioxidant enzyme in the rat substantia nigra.
    J Neurocytol. 2001 Feb;30(2):97-105 PMID: 11577248
  17. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin.
    Science. 2001 Nov 9;294(5545):1307-13 PMID: 11588219
  18. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Science. 2001 Nov 9;294(5545):1346-9 PMID: 11701929
  19. alpha-synuclein and cytosolic dopamine: stabilizing a bad situation.
    Nat Med. 2001 Dec;7(12):1280-2 PMID: 11726961
  20. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.
    J Neurosci. 2001 Dec 15;21(24):9549-60 PMID: 11739566
  21. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders.
    Trends Neurosci. 2001 Nov;24(11 Suppl):S7-14 PMID: 11881748
  22. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity.
    J Neurosci. 2002 Mar 15;22(6):2135-41 PMID: 11896153
  23. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
    Neuropharmacology. 2002 Mar;42(3):367-73 PMID: 11897115
  24. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.
    J Neurochem. 2002 Apr;81(2):301-6 PMID: 12064477
  25. Genetics of Parkinson's disease and biochemical studies of implicated gene products.
    Curr Opin Genet Dev. 2002 Jun;12(3):299-306 PMID: 12076673
  26. Striatal postsynaptic ultrastructural alterations following methylenedioxymethamphetamine administration.
    Ann N Y Acad Sci. 2002 Jun;965:381-98 PMID: 12105114
  27. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.
    J Neurosci. 2002 Oct 15;22(20):8951-60 PMID: 12388602
  28. Etiology of Parkinson's disease: Genetics and environment revisited.
    Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):13972-4 PMID: 12391311
  29. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.
    Cell. 2002 Oct 18;111(2):209-18 PMID: 12408865
  30. Aggresome-related biogenesis of Lewy bodies.
    Eur J Neurosci. 2002 Dec;16(11):2136-48 PMID: 12473081
  31. Altered proteasomal function in sporadic Parkinson's disease.
    Exp Neurol. 2003 Jan;179(1):38-46 PMID: 12504866
  32. The latent membrane protein-1 in Epstein-Barr virus-transformed lymphoblastoid cells is found with ubiquitin-protein conjugates and heat-shock protein 70 in lysosomes oriented around the microtubule organizing centre.
    J Pathol. 1991 Jul;164(3):203-14 PMID: 1653831
  33. Role of dopamine in the neurotoxic effects of methamphetamine.
    J Pharmacol Exp Ther. 1985 Jun;233(3):539-44 PMID: 2409267
  34. A 6-hydroxydopamine-induced selective parkinsonian rat model.
    Brain Res. 1989 Aug 14;494(2):285-93 PMID: 2528389
  35. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
    J Neurochem. 1995 Sep;65(3):1213-20 PMID: 7643100
  36. Pathology and biology of the Lewy body.
    J Neuropathol Exp Neurol. 1993 May;52(3):183-91 PMID: 7684074
  37. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis.
    J Exp Med. 1994 Aug 1;180(2):525-35 PMID: 8046331
  38. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress.
    J Neurosci. 1994 Apr;14(4):2260-71 PMID: 8158268
  39. Neuropathology of Parkinson's disease.
    J Neuropathol Exp Neurol. 1996 Mar;55(3):259-72 PMID: 8786384
  40. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
    Science. 1997 Jun 27;276(5321):2045-7 PMID: 9197268
  41. Alpha-synuclein in Lewy bodies.
    Nature. 1997 Aug 28;388(6645):839-40 PMID: 9278044
  42. Inhibition of striatal energy metabolism produces cell loss in the ipsilateral substantia nigra.
    Brain Res. 1997 Oct 31;773(1-2):223-6 PMID: 9409726
  43. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter.
    J Neurosci. 1998 Mar 15;18(6):1979-86 PMID: 9482784
  44. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.
    Nature. 1998 Apr 9;392(6676):605-8 PMID: 9560156
  45. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice.
    J Neurochem. 1998 May;70(5):1973-8 PMID: 9572281
  46. Parkinson's disease. First of two parts.
    N Engl J Med. 1998 Oct 8;339(15):1044-53 PMID: 9761807
  47. Parkinson's disease. Second of two parts.
    N Engl J Med. 1998 Oct 15;339(16):1130-43 PMID: 9770561
  48. The ubiquitin pathway in Parkinson's disease.
    Nature. 1998 Oct 1;395(6701):451-2 PMID: 9774100
Article Info
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
Abbr.
J Neurosci
ISSN
1529-2401
Published
2003-10-01
Pages
8955-66
Language
English
Region
United States
NLM ID
8102140
PMCID
PMC6740387
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com